TNFa TNF alpha

Home Company Product Technology People Order

TNFa TNF alpha


TNF-a 50% OFF*

Print version *on second equal size

Tumor Necrosis Factor-Alpha (TNF-a), also known as cachectin, is named after its activity to cause tumor necrosis in vivo when injected into tumor-bearing mice. TNF-a is expressed as a 26 kDa membrane bound protein and is then cleaved by TNF-a converting enzyme (TACE) to release the soluble 17 kDa monomer which forms homotrimers in circulation. Recombinant TNF-a exists as homo-dimer, -trimer or -pentamer. TNF-a is believed to play roles in antitumor activity, immune modulation, inflammation, anorexia, cachexia, septic shock, viral replication and ematopoiesis. TNF-a is expressed in many types of cells but primarily in macrophage cells in response to immunological challenges such as bacteria (lipopolysaccharides), viruses, parasites, mitogens and other cytokines. TNF-a is closely related to the 25 kDa protein Tumor Necrosis Factor-b (lymphotoxin) with 28% amino acid sequence identity, sharing the same receptors (TNFR1 and TNFR2) and cellular actions. TNF-a causes cytolysis or cytostasis of many transformed cells, being synergistic with g -interferon in its cytotoxicity. Although it has little effect on many cultured normal human cells, TNF-a appears to be directly toxic to vascular endothelial cells. Other actions of TNF-a include stimulating growth of human fibroblasts and other cell lines, activating polymorphonuclear neutrophils and osteoclasts, and induction of interleukin-1, prostaglandin E2 and collagenase production. Although TNF-a is currently being evaluated in treatment of certain cancers and AIDS-related symptoms, the recombinant TNF-a offered by Biomyx is for research only.



RNA Interference

Dominant Negatives

Protein Labeling

Agar Plates








Contact Us


Phone:(858) 457-3658

Fax:(858) 457-3485


Please type


Recombinant Human Tumor Necrosis Factor a


CAS Number: 94948591

MDL Number: MFCD00148692


Catalog# Package size Price

T1100-20 20g $299

T1100-200 200g $750

T1100-1000 1.0mg $1999

*offer valid on second item of equal size when you purchase one item (catalog numbers T1100-20, -200 or -1000) at list price.

Formulation: Powder lyophilized from volatile buffer 50mM NH4HCO3 (pH 8.0).

Preservative: None.

MW: 17kDa

Purity: >97% (15% SDS-PAGE)

Source: Recombinant protein expressed in E. coli.

Sterility: 0.2 m membrane-filtered and packaged aseptically.

ED50*: 0.01-0.1ng/ml.

Endotoxin**: 0.1 EU/mg TNF-a

QC Tests: SDS-PAGE, Native PAGE, ELISA, Cytolysis, TC



Reconstitution and Use:

Reconstitute the contents of the vial using sterile phosphate-buffered saline (PBS) to a concentration no less than 100 mg/ml and aliquot for future use. (If the initial rehydration is too diluting, activity may be lost due to the non-specific adsorption to the container). The solution can then be further diluted to a working stock solution. Bovine serum albumin can be added to the working solution to protect TNF-a from loss at low concentrations.


If the product is going to be used for applications requiring absolute asepsis (e.g. cell culture), its best to filter-sterilize the solution using a sterile and non-pyrogenic 0.2m membrane before use.


Storage and Stability:

Upon receiving, store the product at -20 C. After reconstitution, store the working aliquots at 2-8 C for no more than 3 months. For extended storage, aliquot the rehydrated solution (100 mg/ml) and freeze at -70 C or -20 C. Avoid repeated freezing and thawing. More dilute solutions stored at -20 C will lose activity faster.

*Cytolysis Assay:

The ED50 is defined as the effective concentration of TNF-a that causes 50% cytolysis of murine L929B cells, a TNF-a sensitive mouse fibrosarcoma cell line, in the presence of actinomycin-D. Results may vary depending on cell line used. (Havell, E.A., 1987).



**Endotoxin Assay:

Endotoxin Unit (EU) is determined by Limulus Amebocyte Lysate (LAL) assay (Sigma).


Further information:


1)       Aggarwal, B., and Reddy, S., Nicola, N., ed., Tumor necrosis factor (TNF) Guidebook to Cytokines and Their Receptors , New York (1994), 103-104

2)       Beutler, B., Sporn, M., and Roberts, A, ed., cachectin/tumor necrosis factor and lymphotoxin Peptide Growth Factors and their Receptors II , New York (1991), 39-70

3)       Callard, R., and Gearing, A., The Cytokine Facts Book , New York (1994),

4)       Ruff, M.R. and G.E. Gifford, Lymphokines 2: 235, 1981.

5)       Eskandari, M.K., et al., Immunol. Invest. 19: 69-79, 1990.

6)       Havell, E.A., J. Immunol. 139: 4225-4231, 1987.

7)       Ware, C., et al., Thomson, A.W., ed., Tumor necrosis factor-related ligands and receptors. The Cytokine Handbook 3rd ed., , San Diego, CA (1998), 549

8)       Matthews, N., et al., Lymphokines and Interferons, A Practical Approach, Clemens, M., et al., eds. IRL Press, 221 (1987).




2004 Biomyx Technology 10054 Mesa Ridge Court Ste. 112 San Diego CA 92121




RNAi siRNA siRNA Dominant Negative Dominant RNAi Negative agar plate agar plates TNFa siRNA cis-enhancer luciferase reporter TNFa cis-enhancer luciferase reporter RNAi TNFa

RNAi RNAi RNAi siRNA siRNA siRNA Dominant Negative Dominant Negative agar plate agar plate cis-enhancer luciferase reporter cis-enhancer luciferase reporter

RNAi RNAi RNAi siRNA siRNA siRNA Dominant Negative Dominant Negative agar plate agar plate cis-enhancer luciferase reporter cis-enhancer luciferase reporter

RNAi RNAi RNAi siRNA siRNA siRNA Dominant Negative Dominant Negative agar plate agar plate cis-enhancer luciferase reporter cis-enhancer luciferase reporter